Cited by 940Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, Jackson G., Kuhns, Michael S., Allison, James P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Integrity signals

Registry

Crossref · 10.1038/ni0702-611

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Show all 93 references

Sorted by citations

Items 301–400 of 940

Cytotoxic T-lymphocyte Antigen-4 Polymorphisms and Susceptibility to Osteosarcoma
Liu, Y., He, Z., Feng, D., Shi, G., Gao, R., Wu, X., Song, W., & Yuan, W. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1269 · Cited by 60
Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer
Groß, S., & Walden, P. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.11.012 · Cited by 60
Breaking down the barriers to cancer immunotherapy
Puré, E., Allison, J. P., & Schreiber, R. D. (2005) · Nature Immunology · doi:10.1038/ni1205-1207 · Cited by 60
Self-citation
Cytochrome P450 pharmacogenetics in African populations: implications for public health
Dandara, C., Swart, M., Mpeta, B., Wonkam, A., & Masimirembwa, C. M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.894020 · Cited by 60
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 61
Development of the PANVAC™-VF vaccine for pancreatic cancer
Petrulio, C., & Kaufman, H. L. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.1.9 · Cited by 60
Decreased Cytotoxic T-Lymphocyte Antigen 4 Expression on Regulatory T Cells and Th17 Cells in Sarcoidosis: Double Trouble?
Broos, C. E., van Nimwegen, M., Veen, J. C. C. M. I. ’., Hoogsteden, H. C., Hendriks, R. W., van den Blink, B., & Kool, M. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0635le · Cited by 59
Molecular aspects of regulatory T cell development
Fontenot, J. D. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2003.12.002 · Cited by 59
Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome
Mirza, S., Hill, E., Ludlow, S. P., & Nanjappa, S. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000326 · Cited by 58
Immunotherapy for pancreatic cancer
Yoon, J. H., Jung, Y.-J., & Moon, S. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i13.2969 · Cited by 58
Digital Genomic Quantification of Tumor-Infiltrating Lymphocytes
Robins, H. S., Ericson, N. G., Guenthoer, J., O'Briant, K. C., Tewari, M., Drescher, C. W., & Bielas, J. H. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007247 · Cited by 58
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
Fassò, M., Waitz, R., Hou, Y., Rim, T., Greenberg, N. M., Shastri, N., Fong, L. H., & Allison, J. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712269105 · Cited by 58
Self-citation
Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses
Palena, C., & Schlom, J. (2010) · BioMed Research International · doi:10.1155/2010/380697 · Cited by 58
T-cell modulatory properties of CD5 and its role in antitumor immune responses
Tabbekh, M., Mokrani, M., Bismuth, G., & Mami‐Chouaib, F. (2012) · OncoImmunology · doi:10.4161/onci.22841 · Cited by 60
South Africa: from species cradle to genomic applications
Hardy, B.-J., Séguin, B., Ramesar, R., SINGER, P. A., & Daar, A. S. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2441 · Cited by 56
Genetic Polymorphisms in Cytotoxic T-Lymphocyte Antigen 4 and Cancer: The Dialectical Nature of Subtle Human Immune Dysregulation
Sun, T., Hu, Z., Shen, H., & Lin, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0176 · Cited by 58
Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors
Skelton, R. A., Javed, A. A., Zheng, L., & He, J. P. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24642 · Cited by 56
E3 Ligases in T Cell Anergy—Turning Immune Responses into Tolerance
Heissmeyer, V., & Rao, A. (2004) · Science s STKE · doi:10.1126/stke.2412004pe29 · Cited by 58
Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors
Mescher, M. F., Popescu, F. E., Gerner, M. Y., Hammerbeck, C. D., & Curtsinger, J. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.008 · Cited by 55
About Face: Forensic Genetic Testing for Race and Visible Traits
Ossorio, P. N. (2006) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2006.00033.x · Cited by 58
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models
Wei, J., Montalvo-Ortiz, W., Yu, L., Krasco, A., Olson, K., Rizvi, S., Fiaschi, N., Coetzee, S., Wang, F., Ullman, E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1082 · Cited by 54
Infiltrating CTLs in Human Glioblastoma Establish Immunological Synapses with Tumorigenic Cells
Barcia, C., Gómez, A., Gallego, J. M., Pérez‐Vallés, A., Castro, M. G., Lowenstein, P. R., Barcia, C., & Herrero, M. T. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081034 · Cited by 54
Ipilimumab: A Novel Treatment for Metastatic Melanoma
Culver, M. E., Gatesman, M. L., Mancl, E. E., & Lowe, D. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p651 · Cited by 54
Single‐cell transcriptomics reveal the intratumoral landscape of infiltrated T‐cell subpopulations in oral squamous cell carcinoma
Chen, J., Yang, J., Li, H., Yang, Z., Zhang, X., Li, X., Wang, J., Zhang, Y., Chen, S., & Song, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12910 · Cited by 57
Changes in Lymphocyte Subsets in the Peripheral Blood of Patients with Active Pulmonary Tuberculosis
Wu, Y., Zhang, S. W., Peng, W., Li, K. S., Li, K., Jiang, J., Lin, J., & Cai, Y. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700610 · Cited by 54
An Important Role of CD80/CD86-CTLA-4 Signaling during Photocarcinogenesis in Mice
Loser, K., Scherer, A., Krummen, M., Varga, G., Higuchi, T., Schwarz, T., Sharpe, A. H., Grabbe, S., Bluestone, J. A., & Beissert, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5298 · Cited by 54
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 56
Roadmap to a Better Therapeutic Tumor Vaccine
Emens, L. A. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992423 · Cited by 53
Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell–Suppressor Mechanisms
Cao, L. Y., Chung, J., Teshima, T., Feigenbaum, L. S., Cruz, P. D., Jacobe, H. T., Chong, B. F., & Ariizumi, K. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.02.816 · Cited by 53
CAR-T cell therapy for lung cancer: a promising but challenging future
Zhong, S., Cui, Y., Liu, Q., & Chen, S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.118 · Cited by 53
Immunotherapy in autoimmune neuromuscular disorders
Gold, R., Dalakas, M. C., & Toyka, K. V. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00264-3 · Cited by 53
Diversity of the Immune Repertoire and Immunoregulation
Schwartz, R. S. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa022766 · Cited by 53
Smart exosomes with lymph node homing and immune-amplifying capacities for enhanced immunotherapy of metastatic breast cancer
Ji, P., Yang, Z., Li, H., Wei, M., Yang, G., Xing, H., & Li, Q. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.10.009 · Cited by 52
Checkpoint immunotherapy in head and neck cancers
Zolkind, P., & Uppaluri, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9694-9 · Cited by 52
CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
Zhang, X., Wu, Y., Xu, T., & Cui, M. (2023) · Biomolecules · doi:10.3390/biom13030465 · Cited by 53
Nanobody-based drug delivery systems for cancer therapy
Liu, L., Tu, B., Sun, Y., Liao, L., Lu, X., Liu, E., & Huang, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.058 · Cited by 51
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
Bograd, A. J., Suzuki, K., Vertes, E. L., Colovos, C., Morales, E. A., Sadelain, M., & Adusumilli, P. S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1103-6 · Cited by 51
The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling
Met, Ö., Wang, M., Pedersen, A. E., Nissen, M. H., Buus, S., & Claësson, M. H. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.02.005 · Cited by 51
Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.
Ma, Y., Liu, X., Zhu, J., Li, W., Guo, L., Han, X., Song, B., Cheng, S., & Liu, J. (2015) · PubMed · Cited by 50
CTLA-4 Blockage Increases Resistance to Infection with the Intracellular Protozoan Trypanosoma cruzi
Martins, G. A., Tadokoro, C. E., Silva, R. B., Silva, J. S., & Rizzo, L. V. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4893 · Cited by 50
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Kim, Y. H., Choi, B. K., Oh, H. S., Kang, W. J., Mittler, R. S., & Kwon, B. S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0993 · Cited by 50
Turning on the off switch: Regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway
Grakoui, A., Wherry, E. J., Hanson, H. L., Walker, C. M., & Ahmed, R. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.07.009 · Cited by 50
A New Role of CTLA-4 on B Cells in Thymus-Dependent Immune Responses In Vivo
Quandt, D., Hoff, H., Rudolph, M., Fillatreau, S., & Brunner-Weinzierl, M. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7316 · Cited by 50
In Situ Programming of Nanovaccines for Lymph Node-Targeted Delivery and Cancer Immunotherapy
Jin, L., Yang, D., Song, Y., Li, D., Xu, W., Zhu, Y., Xu, C., Lü, Y., & Yang, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c06560 · Cited by 49
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma
Eton, O. E., Ross, M. I., East, M. J., Mansfield, P. F., Papadopoulos, N., Ellerhorst, J. A., Bedikian, A. Y., & Lee, J. E. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-9 · Cited by 49
CD70 Deficiency Impairs Effector CD8 T Cell Generation and Viral Clearance but Is Dispensable for the Recall Response to Lymphocytic Choriomeningitis Virus
Munitić, I., Kuka, M., Allam, A., Scoville, J. P., & Ashwell, J. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202353 · Cited by 52
T-cell immunology in sarcoidosis
Broos, C. E., Hendriks, R. W., & Kool, M. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000303 · Cited by 49
Increased Expression of Cytotoxic T-Lymphocyte−Associated Protein 4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients With Acute Liver Failure
Khamri, W., Abeles, R. D., Hou, T. Z., Anderson, A. E., El-Masry, A., Triantafyllou, E., Bernsmeier, C., Larsen, F. S., Singanayagam, A., Kudo, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.023 · Cited by 49
Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer
Park, R., Williamson, S. K., Kasi, A., & Saeed, A. (2018) · Anticancer Research · doi:10.21873/anticanres.12891 · Cited by 49
Dendritic cells: tools and targets for antitumor vaccination
den Brok, M. H., Nierkens, S., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.5.699 · Cited by 52
ICOS+ Th cells produce distinct cytokines in different mucosal immune responses
Bonhagen, K., Liesenfeld, O., Stadecker, M. J., Hutloff, A., Erb, K. J., Coyle, A. J., Lipp, M., Kroczek, R. A., & Kamradt, T. (2003) · European Journal of Immunology · doi:10.1002/immu.200310013 · Cited by 49
Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations
Schirmer, M., Toliat, M. R., Haberl, M., Suk, A., Kamdem, L. K., Klein, K., Brockmöller, J., Nürnberg, P., Zanger, U. M., & Wojnowski, L. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000182779.03180.ba · Cited by 50
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
Kandra, P., Nandigama, R., Eul, B. G., Huber, M., Kobold, S., Seeger, W., Grimminger, F., & Savai, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903562 · Cited by 50
Immunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.003 · Cited by 48
Adoptive T cell therapy: Boosting the immune system to fight cancer
León, E. C., Ranganathan, R., & Savoldo, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101437 · Cited by 48
Targeting CD8 + T-cell Tolerance for Cancer Immunotherapy
Jackson, S. R., Yuan, J., & Teague, R. M. (2014) · Immunotherapy · doi:10.2217/imt.14.51 · Cited by 47
Promises and challenges for the development ofListeria monocytogenes-based immunotherapies
Brockstedt, D. G., & Dubensky, T. W. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.1069 · Cited by 47
Immune Checkpoint Inhibitors in Malignancies with Mismatch Repair Deficiency: A Review of the State of the Current Knowledge
Naboush, A., Roman, C. A. J., & Shapira, I. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000342 · Cited by 48
Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases.
Brunner-Weinzierl, M. C., Hoff, H., & Burmester, G. R. (2004) · Arthritis Research · doi:10.1186/ar1158 · Cited by 47
Future of Cancer Immunotherapy using Plant virus-based Nanoparticles
Shoeb, E., & Hefferon, K. L. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0001 · Cited by 46
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
Farhangnia, P., Ghomi, S. M., Akbarpour, M., & Delbandi, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155778 · Cited by 46
Paradigm Shifts in Cancer Vaccine Therapy
Schlom, J., Gulley, J. L., & Arlen, P. M. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-mr-226 · Cited by 46
Risk for HIV-1 Infection Associated With a Common CXCL12 (SDF1) Polymorphism and CXCR4 Variation in an African Population
Petersen, D. C., Glashoff, R. H., Shrestha, S., Bergeron, J., Laten, A., Gold, B., van Rensburg, E. J., Dean, M. C., & Hayes, V. M. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000186360.42834.28 · Cited by 46
Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators: a systematic review with meta-analyses
Gichohi‐Wainaina, W. N., Towers, G. W., Swinkels, D. W., Zimmermann, M. B., Feskens, E. J. M., & Melse‐Boonstra, A. (2014) · Genes & Nutrition · doi:10.1007/s12263-014-0442-2 · Cited by 46
Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity
Okada, R., Kato, T., Furusawa, A., Inagaki, F. F., Wakiyama, H., Choyke, P. L., & Kobayashi, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000269 · Cited by 46
Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity
Jovasevic, V. M., Gorelik, L., Bluestone, J. A., & MOKYR, M. B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1449 · Cited by 46
International Studies in Dementia With Particular Emphasis on Populations of African Origin
Hendrie, H. C., Murrell, J. R., Gao, S., Unverzagt, F. W., Ogunniyi, A. O., & Hall, K. S. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200607001-00005 · Cited by 47
Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors
Daftarian, P. M., Song, G.-Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D. J., & Ellenhorn, J. D. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0169 · Cited by 46
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
Lee, C., Kakinuma, T., Wang, J., Zhang, H., Palmer, D. C., Restifo, N. P., & Hwang, S. T. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0310 · Cited by 46
HLA class II disease associations in southern Africa
Lombard, Z., Brune, A. E., Hoal, E. G., de Villiers, C. B., van Helden, P. D., Epplen, J. T., & Bornman, L. (2006) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00530.x · Cited by 46
Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities
Tian, J., Guo, F., Zheng, G.-Y., & Ahmad, A. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx141 · Cited by 45
Commentary: Salt, Slavery and Survival— Hypertension in the African Diaspora
Grim, C. E., & Robinson, M. T. (2003) · Epidemiology · doi:10.1097/00001648-200301000-00029 · Cited by 45
Immunotherapy for advanced melanoma: Fulfilling the promise
Gogas, H. J., Polyzos, A., & Kirkwood, J. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.006 · Cited by 47
High IFN-γ Production of Individual CD8 T Lymphocytes Is Controlled by CD152 (CTLA-4)
Pandiyan, P., Hegel, J. K., Krueger, M., Quandt, D., & Brunner-Weinzierl, M. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2132 · Cited by 44
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
Mason, N. J., Chester, N., Xiong, A., Rotolo, A., Wu, Y., Yoshimoto, S., Glassman, P. M., Gulendran, G., & Siegel, D. L. (2021) · mAbs · doi:10.1080/19420862.2021.2004638 · Cited by 44
Clinical studies of vaccines targeting breast cancer.
Ko, B. K., Kawano, K., Murray, J. L., Disis, M. L., Efferson, C. L., Kuerer, H. M., Peoples, G. E., & Ioannides, C. G. (2003) · PubMed · Cited by 44
In Situ Crosslinked Hydrogel Depot for Sustained Antibody Release Improves Immune Checkpoint Blockade Cancer Immunotherapy
Kim, J., Francis, D. M., & Thomas, S. N. (2021) · Nanomaterials · doi:10.3390/nano11020471 · Cited by 43
Genetic structure in four West African population groups
Adeyemo, A., Chen, G., Chen, Y., & Rotimi, C. N. (2005) · BMC Genetics · doi:10.1186/1471-2156-6-38 · Cited by 43
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Wang, X., Zuo, D., Sarkar, D., & Fisher, P. B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629187 · Cited by 44
Extensive Replicative Capacity of Human Central Memory T Cells
Maus, M. V., Kovacs, B., Kwok, W. W., Nepom, G. T., Schlienger, K., Riley, J. L., Allman, D., Finkel, T. H., & June, C. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6675 · Cited by 43
The role of tumor-associated macrophages in oral squamous cell carcinoma
Xue, Y., Song, X. J., Fan, S., & Deng, R. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.959747 · Cited by 44
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity
Bakhru, P., Zhu, M., Wang, H., Hong, L. K., Khan, I. S., Mouchess, M. L., Gulati, A., Starmer, J., Hou, Y., Sailer, D., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93265 · Cited by 44
Profile of ipilimumab and its role in the treatment of metastatic melanoma
Woodman, S. E., & Patel (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s10945 · Cited by 42
Dynamics of T cell activation threshold tuning
van den Berg, H. A., & Rand, D. A. J. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.02.002 · Cited by 42
Genetic interaction of CTLA‐4 with HLA‐DR15 in multiple sclerosis patients
Alizadeh, M., Babron, M., Birebent, B., Matsuda, F., Quelvennec, E., Liblau, R., Cournu‐Rebeix, I., Momigliano‐Richiardi, P., Sequeiros, J., Yaouanq, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10617 · Cited by 42
Mandibular premolar and second molar root morphological variation in modern humans: What root number can tell us about tooth morphogenesis
Shields, E. D. (2005) · American Journal of Physical Anthropology · doi:10.1002/ajpa.20110 · Cited by 41
In vivo overexpression of CTLA‐4 suppresses lymphoproliferative diseases and thymic negative selection
Takahashi, S., Kataoka, H., Hara, S., Yokosuka, T., Takase, K., Yamasaki, S., Kobayashi, W., Saito, Y., & Saito, T. (2005) · European Journal of Immunology · doi:10.1002/eji.200324746 · Cited by 41
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Graff, J. N., Li, Z., & Wu, J. D. (2017) · Science Advances · doi:10.1126/sciadv.1602133 · Cited by 40
Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma
Kämmerer, P. W., Toyoshima, T., Schöder, F., Kämmerer, P., Kuhr, K., Brieger, J., & Al‐Nawas, B. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.03.025 · Cited by 40
IL-10 Has A Distinct Immunoregulatory Effect on Naive and Active T Cell Subsets
Ye, Z., Huang, H., Hao, S., Xu, S., Yu, H. B., Hurk, S. V. D., & Xiang, J. (2007) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.0144 · Cited by 40
Immunotherapy for prostate cancer
Fong, L. H., & Small, E. J. (2006) · Current Urology Reports · doi:10.1007/s11934-006-0027-8 · Cited by 40
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care
Xiao, Y., Li, Z., Zhong, N., Cao, L., Liu, B., & Bu, L. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101794 · Cited by 41
Cytotoxic T-Lymphocyte Antigen-4 +49G/A Polymorphism Is Associated with Increased Risk of Osteosarcoma
Wang, W., Wang, J., Song, H., Liu, J., Song, B., & Cao, X. (2011) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2010.0264 · Cited by 39
Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance
Ocaña‐Guzmán, R., Vazquez-Bolaños, L. A., & Sada‐Ovalle, I. (2018) · Journal of Immunology Research · doi:10.1155/2018/8695157 · Cited by 40
Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction
Sasmal, P., Babasahib, S. K., Kumar, B. R. P., & Raghavendra, N. M. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117001 · Cited by 39
CD152 (CTLA-4) Determines CD4 T Cell Migration In Vitro and In Vivo
Knieke, K., Hoff, H., Maszyna, F., Kolar, P., Schrage, A., Hamann, A., Debes, G. F., & Brunner-Weinzierl, M. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005702 · Cited by 39
HIV may produce inhibitory microRNAs (miRNAs) that block production of CD28, CD4 and some interleukins
Couturier, J. P., & Root-Bernstein, R. S. (2005) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.01.001 · Cited by 39
CTLA-4 Expression and Polymorphisms in Lung Tissue of Patients with Diagnosed Non-Small-Cell Lung Cancer
Antczak, A. J., Pastuszak‐Lewandoska, D., Górski, P., Domańska, D., Migdalska‐Sęk, M., Czarnecka, K. H., Nawrot, E., Kordiak, J., & Brzeziańska‐Lasota, E. (2013) · BioMed Research International · doi:10.1155/2013/576486 · Cited by 38
EGFR and KRAS Mutations, and ALK Fusions: Current Developments and Personalized Therapies for Patients with Advanced Non-Small-Cell Lung Cancer
de Mello, R. A., Madureira, P., Carvalho, L. S., Araújo, A., O'Brien, M. E. R., & Popat, S. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.177 · Cited by 39
Molecular Insights for Optimizing T Cell Receptor Specificity Against Cancer
Hebeisen, M., Oberle, S. G., Presotto, D., Speiser, D. E., Zehn, D., & Rufer, N. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00154 · Cited by 39

Authors: Egen, J. G., Kuhns, M. S., & Allison, J. P.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Allison, James P.
ORCID: Egen, Jackson G.
Kuhns, Michael S.
Allison, James P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-07
Volume: 3
Issue: 7
Pages: 611-618
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni0702-611
OpenAlex: W2140460887
Cited by: 940
References: 93
Citations by year: 2026: 10 · 2025: 15 · 2024: 30 · 2023: 34 · 2022: 45 · 2021: 50 · 2020: 43 · 2019: 33 · 2018: 27 · 2017: 36 · 2016: 28 · 2015: 32 · 2014: 31 · 2013: 38 · 2012: 25
FWCI: 5.88
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (CA40041, R01CA057986, CA57986)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, costimulatory receptors, CD28, T cell activation, T cell receptor signaling, T cell regulation, cancer immunotherapy, CTLA-4 blockade, immune checkpoint blockade
MeSH terms: Abatacept, Animals, Antigens, Differentiation, Cell Division, Colonic Neoplasms, Disease Models, Animal, Fibrosarcoma, Gene Expression Regulation, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antigens, CD, Immunoconjugates, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks